drugset / Trial / NCT00266123

Study Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant Recipients

NCT00266123

Phase 4 Completed 420 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

To demonstrate the superiority of SRL + TAC elimination + corticosteroids (Group I) and SRL + MMF + corticosteroids (Group II) to TAC + MMF + corticosteroids (Group III) with respect to renal allograft function at month 12 post-transplantation.

Timeline

Start
2004-03
Primary completion
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule